28
Views
0
CrossRef citations to date
0
Altmetric
Drug Profile

Insulin aspart: rapid control for postmeal glucose excursions

Pages 587-597 | Published online: 10 Jan 2014
 

Abstract

Insulin aspart is a rapid-acting insulin analog that can be used to control prandial glucose levels as part of basal–bolus therapy, in continuous subcutaneous insulin infusion or in combination with oral antidiabetic drugs. Compared with exogenous human soluble insulin, insulin aspart has a faster onset of action, a higher peak concentration and a shorter duration of action, and is therefore more comparable to the physiological prandial insulin response. Randomized clinical trials have shown efficacy and safety advantages with insulin aspart over human soluble insulin, in particular, improved postprandial glucose control and lower rates of hypoglycemia. Currently, insulin aspart has been approved for use not only in adults and children with diabetes mellitus, but also for pregnant women with diabetes, including those with gestational diabetes.

Financial disclosure

Jens Sandahl Christiansen has received fees for speaking at international symposia, unrestricted funds for research and fees from consulting from Pfizer, Novo Nordisk, Novartis and Ferring.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 608.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.